Methods of using usp15 inhibitors
AssigneeThe Curators of the University of Missouri
InventorThang VAN NGUYEN
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally directed to compositions and methods related to USP15 inhibitors. More particularly, the present disclosure relates to methods of regulating CRL4CRBN-USP15 pathway (previously referred to as the CRL4CRBN-p97 pathway) and glutamine synthetase levels and methods of treating diseases such as cancer via administration of USP15 inhibitors.
Claims19
A method of treating cancer in a subject in need thereof, the method comprising:
- administering to the subject in need thereof a therapeutically effective amount of a USP15 inhibitor and at least one chemotherapeutic drug.
A method of diagnosing and treating resistance to IMiD therapy in a subject with multiple myeloma undergoing IMiD therapy, the method comprising:
- a) measuring an amount of USP15 protein in the subject;
- b) comparing the amount of USP15 protein in the subject to a reference;
- c) diagnosing the subject with resistance to IMiD therapy if the amount of USP15 protein in the subject is higher than the reference;
- and
- d) administering a USP15 inhibitor to the subject.
A method of regulating CRL4CRB-USP15 pathway and glutamine synthetase levels in a subject comprising administering a USP15 inhibitor to the subject.
Dependencies are inferred from the claim text.